Search results
Results from the WOW.Com Content Network
It is similar in function to the Food and Drug Administration in the United States, the Medicines and Healthcare products Regulatory Agency in the United Kingdom, the Spanish Agency of Medicines and Medical Devices in Spain or the Food and Drug Administration in the Philippines. [2] The PhMDA has been eCTD compliant at least since December 2017 ...
Sakigake (さきがけ, lit. "pathfinder", "harbinger") is a drug designation by the Pharmaceuticals and Medical Devices Agency, the pharmaceuticals regulator of Japan. It was designed to provide easier access to novel advanced treatments. [1]
A stringent regulatory authority is a regulatory authority which is: a) a member of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH), being the European Commission, the US Food and Drug Administration and the Ministry of Health, Labour and Welfare of Japan also represented by the Pharmaceuticals and Medical Devices Agency (as before ...
The drug, which is already approved in Japan has faced a long path to the U.S. market, with the Food and Drug Administration (FDA) declining to approve it in 2019 in a different set of acute ...
NMPA headquarters Food & Drug Administration enforcement badge of China. The National Medical Products Administration (NMPA; [1] 国家药品监督管理局) is a national bureau responsible for drug supervision under the State Council of China and is managed by the State Administration for Market Regulation.
In this list of financial regulatory and supervisory authorities, central banks are only listed where they act as direct supervisors of individual financial firms, and competition authorities and takeover panels are not listed unless they are set up exclusively for financial services.
The claim: Japan declared COVID-19 vaccine is ‘the most deadly drug in history’ A Nov. 8 Facebook post (direct link, archive link) claims another country issued a dire warning about the COVID ...
Ipragliflozin (INN, [2]: 69 trade names Suglat) is a pharmaceutical drug for treatment of type 2 diabetes. Ipragliflozin, jointly developed by Astellas Pharma and Kotobuki Pharmaceutical, was approved in Japan on January 17, 2014, [3] and in Russia on May 22, 2019. [4] Ipragliflozin is a Sodium/glucose cotransporter 2 (SGLT2) inhibitor . [5]